SCHEMBL3906111

SCHEMBL3906111

Cc1cccc(Cl)c1C(=O)NC(c1ccccc1)C(C)(C)N(C)C

nearest known ligand 0.50

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
UTS2R Q9UKP6 1/20 0.50
ITGB2 P05107 1/20 0.46
ICAM1 P05362 1/20 0.46
ITGAL P20701 1/20 0.46
ITGB1 P05556 7/20 0.44
ITGA4 P13612 7/20 0.44
ITGB7 P26010 3/20 0.44
ITGA2 P17301 1/20 0.44
TYK2 P29597 1/20 0.42
LMNA P02545 2/20 0.41
SLC6A9 P48067 4/20 0.41
ALDH1A1 P00352 1/20 0.40
SMN1; SMN2 Q16637 1/20 0.40
L3MBTL1 Q9Y468 1/20 0.40
MEN1 O00255 1/20 0.38
KMT2A Q03164 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3902170 0.92 LMNA (0.44) UTS2RITGB1ITGA4LMNASLC6A9
SCHEMBL3907148 0.91 SLC6A9 (0.47) UTS2RITGB2ICAM1ITGALLMNA
SCHEMBL3904017 0.87 LMNA (0.40) UTS2RITGB2ICAM1ITGALLMNA
SCHEMBL3914045 0.87 LMNA (0.40) UTS2RITGB1ITGA4LMNASLC6A9
SCHEMBL3240255 0.86 UTS2R (0.49) UTS2RITGB2ICAM1ITGALITGB1
SCHEMBL3902029 0.86 ITGB1 (0.43) ITGB1ITGA4ITGB7LMNASLC6A9
SCHEMBL3903930 0.85 SLC6A9 (0.41) UTS2RITGB2ICAM1ITGALITGB1
SCHEMBL3905138 0.84 ATM (0.44) SLC6A9ALDH1A1L3MBTL1MEN1KMT2A
SCHEMBL3905654 0.84 LMNA (0.42) UTS2RLMNASLC6A9ALDH1A1SMN1; SMN2
SCHEMBL3901138 0.83 UTS2R (0.41) UTS2RITGB1ITGA4LMNASLC6A9

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1838663-B1 GLYCINE TRANSPORT INHIBITORS GLAXO GROUP LTD (GB) 2009-01-21 EP claimed
US-20090270510-A1 GLYCINE TRANSPORT INHIBITORS GLAXO GROUP LIMITED (GB) 2009-10-29 US disclosed
US-20090270510-A1 GLYCINE TRANSPORT INHIBITORS GLAXO GROUP LIMITED (GB) 2009-10-29 US disclosed
US-20090270510-A1 GLYCINE TRANSPORT INHIBITORS GLAXO GROUP LIMITED (GB) 2009-10-29 US disclosed
EP-1838663-B1 GLYCINE TRANSPORT INHIBITORS GLAXO GROUP LTD (GB) 2009-01-21 EP disclosed
WO-2006067417-A1 GLYCINE TRANSPORT INHIBITORS GLAXO GROUP LIMITED (GB) 2006-06-29 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090270510-A1 GLYCINE TRANSPORT INHIBITORS SLC18A2, SLC6A5, SLC1A2 UTS2R 3095/4885ITGB2 4801/4885ICAM1 1974/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.